At week @ , the PASI @ response rates were higher with brodalumab at the @-mg and @-mg doses than with placebo ( @ % and @ % , respectively , vs. @ % -LSB- AMAGINE-@ -RSB- and @ % and @ % , respectively , vs. @ % -LSB- AMAGINE-@ -RSB- ; P < @ ) ; the rates of sPGA scores of @ or @ were also higher with brodalumab ( P < @ ) .